Drug intelligence / Profile preview

V404 PDS

Development stage: Discontinued
Modality: Small Molecules

Overview

V404 PDS is a drug candidate that was investigated for its safety and preliminary efficacy in patients with chronic non-infectious uveitis, specifically posterior and intermediate uveitis. The clinical study for this drug has been terminated.

Other names: Methotrexate Port Delivery SystemMethotrexate PDSV404 Port Delivery SystemV-404 Port Delivery SystemV 404 Port Delivery System

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on V404 PDS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V404 PDS.

Explore the full profile